**Core tip:** The association between *Helicobacter pylori* (*H. pylori*) infection and obesity/weight gain is still unclear and controversial. We performed this retrospective study with a large sample size to explore the association between *H. pylori* infection and obesity/weight gain in Chinese people. The change in body mass index and the prevalence of obesity over two years in the *H. pylori* (+) group were not significantly higher than those in the *H. pylori* (-) group. We concluded that *H. pylori* infection was not associated with overweight/obesity observed from this study of Chinese people.

INTRODUCTION
============

Obesity is defined as excessive fat accumulation that may impair health. The World Health Organization estimated that over 600 million people in the world were obese in the year 2014. The worldwide prevalence of obesity more than doubled between 1980 and 2014. Obesity is associated with infectious diseases, such that certain infections may trigger an increase in adiposity, such as human adenovirus 36, H1N1/influenza virus, human immunodeficiency virus, and *Helicobacter pylori* (*H. pylori*)\[[@B1]\].

*H. pylori* is one of the most common human infections, and it is estimated that more than half of the world's population are infected\[[@B2]\]. *H. pylori* has been linked to gastritis, gastric ulcers and gastric cancer\[[@B3]-[@B5]\]. The association between *H. pylori* and obesity/weight gain remains unclear and controversial.

The prevalence of *H. pylori* infection was reported to be from 8.7% to 85.5%\[[@B6]\]. A lower prevalence of *H. pylori* infection was found in obese patients than in the general population\[[@B6]\]. Other studies have reported a higher *H. pylori* prevalence in obese patients\[[@B7],[@B8]\]. The systematic review by Dhurandhar et al\[[@B1]\] reported an increase in weight gain or an increase in the biomarkers associated with weight gain after *H. pylori* eradication, and most cross-sectional studies found evidence of a higher prevalence of *H. pylori* infection in obese individuals or metabolic impairment in the presence of the infection.

One study indicated an inverse relationship between morbid obesity and *H. pylori* seropositivity, leading to the hypothesis that the absence of *H. pylori* infection during childhood may enhance the risk of developing morbid obesity\[[@B9]\]. The significant increase in body mass index (BMI) observed after eradication of *H. pylori* highlights a possible inverse correlation between *H. pylori* infection and obesity\[[@B10],[@B11]\]. Several studies did not find any influence of bacterial eradication on body weight\[[@B12],[@B13]\]. In a large randomized controlled study, Lane and colleagues found a significant increase in body mass following eradication of *H. pylori* in a European population\[[@B10]\]. A meta-analysis of 18 observational studies including 10000 subjects found a higher body mass index among *H. pylori*-positive subjects compared with *H. pylori*-negative subjects\[[@B14]\]. A cross-sectional study showed that *H. pylori* infection was significantly and positively associated with overweight/obesity in a Chinese population\[[@B15]\]. Reports from different areas and countries were not consistent with each other, and most were cross-sectional studies. It is therefore necessary to further explore the true association between *H. pylori* infection and obesity.

Therefore, we performed this retrospective study to explore the association between *H. pylori* infection and obesity/weight gain in a Chinese population.

MATERIALS AND METHODS
=====================

Study design and participants
-----------------------------

This observational retrospective study was performed at the Aerospace Center Hospital in Beijing, China. The data of all the subjects from a certain unit who underwent health examination in 2012 were retrieved from the registration system. The subjects without *H. pylori* detection results or data regarding height/weight were excluded. We then searched the data regarding height and weight of the same patient population in 2013.

We performed a chart review of all recruited subjects to collect the information regarding demographic characteristics, underlying diseases (diabetes, hypertension and coronary heart disease), and laboratory test results, including low density lipoprotein (LDL), high density lipoprotein (HDL), triglycerides (TG), total cholesterol (TC) and fasting blood-glucose (FBG). The height and weight of all the subjects were measured at baseline and at 1-year follow-up. *H. pylori* status was estimated by enzyme linked immunosorbent assay (ELISA) for anti-*H. pylori* IgG and IgM. This study was performed with the approval of the Ethical Committees of the hospital. The methods were carried out in accordance with the approved guidelines. At recruitment, written informed consent was obtained from all subjects.

Outcomes
--------

Our primary outcome was the change in BMI. The secondary outcome was the prevalence of obesity.

Statistical analysis
--------------------

BMI was calculated as the weight (kg) divided by the square of the height (m). Obesity was defined as BMI equal to or greater than 28 kg/m^2^, and overweight was defined as BMI equal to or greater than 24 kg/m^2^ and less than 28 kg/m^2^, as recommended by the Working Group on Obesity in China\[[@B16]\]. Descriptive statistics were performed, with continuous variables summarized as median and range and categorical variables as frequencies and proportions. The statistical significance between groups was tested using the *χ*^2^-test or Fisher's exact test for categorical variables and the independent *t* test for continuous variables. Generalized linear models were used to explore the association between *H. pylori* infection and the change in BMI. Logistic regression models were used to explore the association between *H. pylori* infection and obesity. The variables of age, sex, marital status, underlying disease, LDL, HDL, TGs, TC and FBG were adjusted in the above models. Risk ratios (RRs) and their 95%CIs were estimated. A two-sided *P* value \< 0.05 was considered statistically significant. All analyses were performed using Stata 12.0 (Stata Corp LP, College Station, TX, United States).

RESULTS
=======

Subjects
--------

A total of 16462 subjects participated in the health examination at the hospital. The diagram of the selection of subjects in the study is shown in Figure [1](#F1){ref-type="fig"}. Among all the subjects, 13390 were excluded due to the absence of *H. pylori* detection results or BMI data, and 33 (1.1%) subjects were lost to follow-up. Finally, 3039 subjects were recruited and analyzed.

![The flow diagram of the subject selection in the study.](WJG-23-2750-g001){#F1}

The characteristics of the subjects in this study are shown in Table [1](#T1){ref-type="table"}. The mean (SD) age of all the subjects was 49 (19) years, and 248 (8.2%) were female. A total of 770 (22.5%) subjects had underlying diseases, including 21.1% with hypertension, 6.8% with diabetes and 5.8% with coronary heart disease. The mean (standard deviation) BMI was 24.5 (3.3) kg/m^2^. Most (44.2%) of the subjects had normal weight, 41.0% were overweight and 12.8% were obese.

###### 

The characteristics of subjects at study baseline *n* (%)

  **Variable**             **Total (*n* = 3039)**   **Baseline data**                
  ------------------------ ------------------------ ------------------- ------------ ----------
  Age (yr), mean ± SD      49 ± 19                  50 ± 19             47 ± 19      \< 0.001
  ≤ 45                     1513 (49.8)              737 (48.7)          776 (51.3)   \< 0.001
  45-60                    523 (17.2)               319 (61.0)          204 (39.0)   
  \> 60                    1003 (33.0)              583 (58.1)          420 (41.9)   
  Sex, female              248 (8.2)                137 (55.4)          111 (44.6)   0.662
  Marriage, single         734 (24.2)               358 (48.8)          376 (51.2)   0.001
  Underlying disease       770 (25.4)               446 (57.9)          324 (42.1)   0.010
  Diabetes                 207 (6.8)                121 (58.5)          86 (41.6)    0.175
  Hypertension             642 (21.1)               369 (57.5)          273 (42.5)   0.042
  Coronary heart disease   177 (5.8)                99 (55.9)           78 (44.1)    0.579
  LDL \> 3.1 mmol/L        816 (28.1)               465 (57.0)          351 (43.0)   0.092
  HDL \< 0.83 mmol/L       823 (28.4)               469 (57.0)          354 (43.0)   0.090
  TG \> 1.71 mmol/L        861 (28.3)               488 (56.7)          373 (43.3)   0.056
  TC \> 5.7 mmol/L         614 (20.2)               336 (54.7)          278 (45.3)   0.660
  FBG \> 6.1 mmol/L        439 (14.5)               258 (58.8)          181 (41.2)   0.028
  BMI, kg/m^2^             24.5 ± 3.3               24.5 ± 3.2          24.4 ± 3.3   0.221
  Underweight              62 (2.0)                 34 (54.8)           28 (45.2)    0.146
  Normal                   1342 (44.2)              693 (51.6)          649 (48.4)   
  Overweight               1247 (41.0)              700 (56.1)          547 (43.9)   
  Obese                    388 (12.8)               212 (54.6)          176 (45.4)   

BMI: Body mass index; LDL: Low density lipoprotein; HDL: High density lipoprotein; FBG: Fasting blood glucose; TG: Triglycerides; TC: Total cholesterol; *H. pylori*: *Helicobacter pylori*.

H. pylori distribution
----------------------

The overall prevalence of *H. pylori* infection was 53.9% (1639/3039), and the prevalence was 54.6% (212/388) in the obese subjects. Higher rates of seroprevalence were demonstrated in the subjects who were older, married, had underlying diseases, hypertension or higher FBG (all *P* \< 0.05), as shown in Table [1](#T1){ref-type="table"}. No significant associations were found between *H. pylori* and BMI/obesity at the baseline survey (*P* \> 0.05).

Association between H. pylori and BMI
-------------------------------------

Observed from all the subjects, the BMI decreased from the baseline to the 1-year follow-up in both the *H. pylori* (+) group (*r* = -0.169, Figure [2A](#F2){ref-type="fig"}) and the *H. pylori* (-) group (*r* = -0.189, Figure [2B](#F2){ref-type="fig"}). However, the change in BMI in the *H. pylori* (+) group was not significantly higher than that in the *H. pylori* (-) group after adjusting for age, sex, marriage, underlying disease, LDL, HDL, TGs, TC and FBG (RR = 0.988, 95%CI: 0.924-1.057, *P* = 0.729), as shown in Table [2](#T2){ref-type="table"}. BMI significantly decreased in the overweight and obese subjects at the 1-year follow-up, while it was non-significantly increased in the underweight and normal weight subjects (Table [2](#T2){ref-type="table"} and Figure [3](#F3){ref-type="fig"}). Differences were not found between *H. pylori* infection and BMI change in different BMI groups (*P* \> 0.05 for all).

###### 

The association between *Helicobacter pylori* and body mass index in the study

  **Group**                                             **Change in BMI**   **Crude**   **Adjusted**                                         
  ----------------------------------------------------- ------------------- ----------- --------------------- ------- ---------------------- -------
  Model 1 in all the subjects                                                                                                                
  *H. pylori* (+)                                       -0.118              \< 0.001    0.963 (0.901-1.029)   0.264   0.988 (0.924-1.057)    0.729
  *H. pylori* (-)                                       -0.080              \< 0.001    1.000                         1.000                  
  Model 2 in the subjects with obesity                                                                                                       
  *H. pylori* (+)                                       -0.431              \< 0.001    1.020 (0.791-1.317)   0.876   1.038 (0.794-1.357)    0.786
  *H. pylori* (-)                                       -0.411              \< 0.001    1.000                         1.000                  
  Model 3 in the subjects with overweight                                                                                                    
  *H. pylori* (+)                                       -0.136              \< 0.001    0.942 (0.852-1.042)   0.245   0.968 (0.874, 1.072)   0.529
  *H. pylori* (-)                                       -0.196              \< 0.001    1.000                         1.000                  
  Model 4 in the subjects with normal and underweight                                                                                        
  *H. pylori* (+)                                       0.0563              0.159       0.987 (0.908-1.074)   0.764   1.009 (0.926-1.1)      0.835
  *H. pylori* (-)                                       0.0435              0.057       1.000                         1.000                  

*H. pylori*: *Helicobacter pylori*.

![The scatter plots of change in body mass index along with body mass index at baseline in the *Helicobacter pylori* (+) and *Helicobacter pylori* (-) groups. The trend lines are added in the two plots. A: *Helicobacter pylori* (*H. pylori*) (+) group; B: *H. pylori* (-) group. BMI: Body mass index.](WJG-23-2750-g002){#F2}

![The scatter plots of change in body mass index in the underweight, normal, overweight and obese subjects at baseline in the *Helicobacter pylori* (+) and *Helicobacter pylori* (-) groups. The means are added in the two plots. A: *Helicobacter pylori* (*H. pylori*) (+) group; B: *H. pylori* (-) group. BMI: Body mass index.](WJG-23-2750-g003){#F3}

Association between H. pylori and obesity
-----------------------------------------

The prevalence of obesity decreased 1.1% in the *H. pylori* (+) group and 0.5% in the *H. pylori* (-) group (Table [3](#T3){ref-type="table"}). The RR of *H. pylori* infection for obesity was 0.831 (95%CI: 0.577-1.197; *P* = 0.321) after the adjustment. In the obese subjects, the decreased prevalence of obesity was 19.9% and 19.1% in the *H. pylori* (+) and the *H. pylori* (-) group, respectively. Compared with the *H. pylori* (-) group, the subjects in the *H. pylori* (+) group lost weight more easily (RR = 0.931; 95%CI: 0.574-1.585; *P* = 0.972). In the non-obese subjects, the prevalence of obesity in the *H. pylori* (+) group was lower than that in the *H. pylori* (-) group (RR = 0.673; 95%CI: 0.382-1.186; *P* = 0.170).

###### 

The association between *Helicobacter pylori* and obesity in the study

  **Group**                           **Event**    **Crude**    **Adjusted**                                                       
  ----------------------------------- ------------ ------------ -------------- --------------------- ------- --------------------- -------
  Model 1 in all the subjects                                                                                                      
  *H. pylori* (+)                     212 (12.9)   194 (11.8)   18 (1.1)       0.890 (0.626-1.267)   0.519   0.831 (0.577-1.197)   0.321
  *H. pylori* (-)                     176 (12.6)   169 (12.1)   7 (0.5)        1.000                         1.000                 
  Model 2 in the obese subjects                                                                                                    
  *H. pylori* (+)                     212 (100)    170 (80.2)   42 (19.8)      0.995 (0.603-1.642)   0.985   0.931 (0.547-1.585)   0.792
  *H. pylori* (-)                     176 (100)    141 (80.1)   35 (19.1)      1.000                         1.000                 
  Model 3 in the non-obese subjects                                                                                                
  *H. pylori* (+)                     0            24 (1.7)     24 (1.7)       0.731 (0.422-1.268)   0.265   0.673 (0.382-1.186)   0.170
  *H. pylori* (-)                     0            28 (2.3)     28 (2.3)       1.000                         1.000                 

Note: The population is the same as that in Table [2](#T2){ref-type="table"}. *H. pylori*: *Helicobacter pylori*.

DISCUSSION
==========

We evaluated the relationship between *H. pylori* infection and obesity/weight gain in the population using a retrospective study. No significant differences were found during the analysis. Despite the lack of significant differences, we found a trend toward weight loss in conjunction with *H. pylori* infection.

The prevalence of *H. pylori* in the overall population was 53.9%, which was similar to those in other Asian countries (Japan and Taiwan), lower than those in most European and South American countries and higher than those in North America and Australia\[[@B6]\]. These discrepancies might be related to both small sample size and variability in diagnostic testing. Different methods were used to diagnose *H. pylori* infection. Serology had a low diagnostic accuracy of only 80%-84%, which is only useful to exclude *H. pylori*, while the urea breath test (UBT) performed better with a sensitivity of 88%-95% and a specificity of 95%-100%\[[@B6]\]. Therefore, in order to give a correct diagnosis, positive serology and UBT should be performed together before treatment.

Some studies reported that eradication of *H. pylori* was associated with metabolic disturbances including weight gain\[[@B17]-[@B19]\]. Some studies have given an explanation about the effect of *H. pylori* eradication; one was that *H. pylori* eradication increases the gastric secretion of ghrelin, which leads to increased appetite and weight gain\[[@B20],[@B21]\]. The precise effect of gastric secretion of ghrelin on circulating ghrelin levels is not straightforward. Another explanation was that the eradication of *H. pylori* decreases gastric leptin expression, and this decrease was accompanied by an increase in BMI\[[@B22]\]. The effects of *H. pylori* on ghrelin and leptin strongly suggest that the bacterium "protects" against obesity. The decreasing incidence of this infection may be contributing to an increase in appetite and food intake. Unfortunately, these mechanisms were not invariably confirmed. Epidemiological studies have failed to show any association between *H. pylori* infection and BMI, although a meta-analysis of 18 observational studies reported a slightly higher BMI in *H. pylori* positive patients\[[@B14]\]. In our study, the *H. pylori* infection appeared to be a protective factor for obesity. The *H. pylori* (+) subjects had decreased BMI more than *H. pylori* (-) subjects, although the differences were not significant, which is opposite to the result of the cross-sectional study by Zhang et al\[[@B15]\]. This contrary finding may be attributed to different populations being analyzed and/or the different methods used to make the diagnosis. Another reason may be the increase in intestinal permeability and the role of gut microbiota to induce insulin resistance and liver steatosis\[[@B23],[@B24]\]. Based on that, we think that *H. pylori* infection may have a limited effect in losing weight, and the eradication of *H. pylori* may have a limited effect in gaining weight. The primary cause of weight gain is changes in lifestyle. The intake of fat and carbohydrates increases, while physical activity clearly decreases. *H. pylori* infection was associated with decreased gastric expression of leptin and ghrelin and correlated negatively with patient energy intake and body mass index\[[@B25]\]. It can be postulated that *H. pylori* infection due to effects on leptin and ghrelin protects against the intake of a large amount of calories in these patients.

Our study had several important limitations. The primary limitation is that our study had a short-term follow-up (only one year), and we could not achieve a significant outcome from the portion of the subjects who attended follow-up. Another limitation is that we did not consider the effect of the treatment on the *H. pylori* infection during the follow-up time, which may influence the association between *H. pylori* infection and weight gain. We did not analyze the effect of insulin resistance on the association between *H. pylori* and obesity. Serological testing for the presence of anti-*H. pylori* IgG and IgM does not indicate a current infection and only shows exposure to these bacteria, which may have biased the detection of *H. pylori* infection. The last limitation is that the ratio of males to females was high due to the characteristics of the unit from which the subjected came. These above limitations may have biased certain outcomes of the results.

In conclusion, *H. pylori* infection was not associated with overweight/obesity observed in the retrospective study in this Chinese population.
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Research frontiers
------------------

Some studies reported that the eradication of *H. pylori* was associated with metabolic disturbances including weight gain, but the mechanisms were not invariably confirmed. Epidemiological studies have failed to show any association between *H. pylori* infection and body mass index.

Innovations and breakthroughs
-----------------------------

No significant differences were found between *H. pylori* infection and obesity/weight gain during the analysis. In spite of this, the authors also found a trend toward weight loss with *H. pylori* infection.

Applications
------------

These results provide evidence that *H. pylori* infection may be not associated with obesity or weight gain, which means that *H. pylori* infection may have a limited effect in weight loss; that is, eradication of *H. pylori* may have a limited effect in gaining weight.
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